Literature DB >> 2540705

Mycobacteria and the new quinolones.

D C Leysen1, A Haemers, S R Pattyn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2540705      PMCID： PMC171410          DOI： 10.1128/AAC.33.1.1

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  65 in total

1.  Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.

Authors:  C Easmon; L Verity
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

2.  In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.

Authors:  O G Berlin; L S Young; D A Bruckner
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

3.  In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  P Hohl; M Salfinger; F M Kafader
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  Comparative in-vitro activity of five fluoroquinolones against mycobacteria.

Authors:  S Davies; P D Sparham; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

5.  Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.

Authors:  L S Young; O G Berlin; C B Inderlied
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 6.  Drug interactions of ciprofloxacin with other non-antibiotic agents.

Authors:  E Rubinstein; S Segev
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 7.  Ciprofloxacin: an overview of adverse experiences.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

8.  Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.

Authors:  F P Maesen; B I Davies; C Baur; C A Sumajow
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

Review 9.  Comparative pharmacokinetic parameters of new systemic fluoroquinolones.

Authors:  M Neuman
Journal:  Int J Clin Pharmacol Res       Date:  1987

10.  Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection.

Authors:  C M Licitra; R G Brooks; B E Sieger
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191
View more
  44 in total

1.  The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

Authors:  S P Saini; A K Srivastava
Journal:  Vet Res Commun       Date:  2001-12       Impact factor: 2.459

2.  Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Authors:  Jean-Noël Dauendorffer; Isabelle Guillemin; Alexandra Aubry; Chantal Truffot-Pernot; Wladimir Sougakoff; Vincent Jarlier; Emmanuelle Cambau
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

3.  Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves.

Authors:  A K Srivastava; V K Dumka; S S Deol
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

Review 4.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Agents of newly recognized or infrequently encountered mycobacterial diseases.

Authors:  L G Wayne; H A Sramek
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

6.  Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice.

Authors:  H Tomioka; K Sato; H Saito
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

7.  Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.

Authors:  R Gozalbes; M Brun-Pascaud; R García-Domenech; J Gálvez; P M Girard; J P Doucet; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

8.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 9.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Quinolones in intracellular infections.

Authors:  J C Pechère
Journal:  Drugs       Date:  1993       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.